Company: DVAX
Filing Date: 2025-05-19
Form Type: DFAN14A
Source: 0001193125-25-122435
Chunk: 5

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-19
Form: DFAN14A
Chunk 5
---
 Medigen Vaccine Biologics Corp. PHASE1 45 NCT04671017 12/16/2020 COMPLETED SARS-CoV-2 Virus Infection Valneva Austria GmbH PHASE1|PHASE2 153 NCT04830800 3/10/2021 COMPLETED COVID-19 Disease|SARS Pneumonia|Pneumonia, Viral|COVID-19 Vaccine Institute of Vaccines and Medical Biologicals, Vietnam PHASE1 120 NCT04764422 3/20/2021 COMPLETED Covid-19|SARS Pneumonia|Pneumonia, Viral|Covid-19 Vaccine Mahidol University PHASE1|PHASE2 455 NCT04672395 3/24/2021 COMPLETED COVID-19 Clover Biopharmaceuticals AUS Pty PHASE2|PHASE3 31454 NCT04864561 4/26/2021 COMPLETED SARS-CoV-2 Virus Infection Valneva Austria GmbH PHASE3 4034 NCT04956224 8/9/2021 COMPLETED SARS-CoV-2 Virus Infection Valneva Austria GmbH PHASE3 306 NCT04954131 8/10/2021 UNKNOWN COVID-19 Zhejiang Clover Biopharmaceuticals, Inc. PHASE2 766 NCT04950751 08/2021 WITHDRAWN COVID-19 Clover Biopharmaceuticals AUS Pty PHASE2 0 NCT05012787 11/12/2021 TERMINATED COVID-19 Clover Biopharmaceuticals AUS Pty PHASE3 1 NCT05087368 12/1/2021 UNKNOWN Covid19 D'Or Institute for Research and Education PHASE2 520 NCT05245838 1/10/2022 COMPLETED Shingles|Herpes Zoster|Vaccine-Preventable Diseases Dynavax Technologies Corporation PHASE1 150 NCT05228613 2/16/2022 COMPLETED COVID-19 PT Bio Farma PHASE1 175 NCT05313035 4/13/2022 COMPLETED COVID-19 PT Bio Farma PHASE2|PHASE3 360 NCT05364242 5/9/2022 COMPLETED SARS-CoV-2 Infection Valneva Austria GmbH PHASE2|PHASE3 178 NCT054